Mergers and Acquisitions in the IVD Market - ResearchAndMarkets.com

Published: Apr 13, 2018

DUBLIN--(BUSINESS WIRE)-- The "Mergers and Acquisitions in the IVD Market" report has been added to Research And Markets' offering.

As a means to more effectively address competitive pressures by capitalizing on economics of scale and scope, the in vitro diagnostics (IVD) industry continues to experience consolidations. Many of these transactions occur cross-border, particularly with U.S. and European companies seeking to enter Asia. Many also involve the acquisition of specific product lines or business units, rather than entire corporations. This report looks at market transactions in Mergers and Acquisitions in the IVD Market, recording over 220 acquisitions in the diagnostics industry from 2015 to March 2018.

The U.S. tax legislation passed in December 2017 is expected to support increased M&A activity through significantly lower corporate taxes that will provide capital for deals. This, combined with continued low interest rates and opportunities for increasing profits and/or revenues through M&A, will support M&A activity moving forward.

Examples of market segments or approaches to market segments in which there have been significant acquisitions include the following:

  • Gene Editing
  • Liquid Biopsy
  • Microbiome
  • Next-Generation Sequencing
  • Automation, and the Introduction of New, Large, Automated Platforms
  • Rapid Point-of-Care Testing with Single Pathogen Infectious Disease Tests
  • Connectivity
  • Looking to the East

Among the specific acquisitions discussed in the report are:

  • Abbott's acquisition of Alere and related divestures
  • Bio-Rad's acquisition of ddPCR developer RainDance
  • Konica Minolta's entry into the health and life sciences space with the acquisition of Ambry Genetics
  • Danaher's acquisition of molecular diagnostics leader Cepheid

Companies Mentioned

  • Abbott
  • Agilent
  • Ambry Genetics
  • Becton Dickinson (BD)
  • Bio-Rad
  • Bruker
  • CareFusion
  • Cathay Fortune International
  • Celgene
  • Charles River Labs
  • Chembio Diagnostics
  • Curetis
  • Danaher
  • Debiopharm Group
  • Enterome
  • Grifols
  • IBM Healthcare/Watson
  • Immucor
  • Johnson & Johnson
  • Konica Minolta
  • LabCorp
  • llumina
  • Luminex
  • Nestle Health Science
  • Oxford Gene Technology (OGT)
  • PerkinElmer
  • QIAGEN
  • Quest and DiaSorin
  • Quidel
  • Roche
  • RVR Diagnostics
  • Sanofi
  • Siemens
  • Sysmex
  • Thermo Fisher Scientific

Key Topics Covered:

1. Executive Summary

2. IVD Mergers and Acquisitions

For more information about this report visit https://www.researchandmarkets.com/research/qqmfsd/mergers_and?w=4

 

Back to news